{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T05:06:50Z","timestamp":1722402410631},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[1985,9,1]],"date-time":"1985-09-01T00:00:00Z","timestamp":494380800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[1985,9]]},"DOI":"10.1007\/bf00431770","type":"journal-article","created":{"date-parts":[[2004,11,10]],"date-time":"2004-11-10T23:25:45Z","timestamp":1100129145000},"page":"16-19","source":"Crossref","is-referenced-by-count":38,"title":["Therapeutic advantages of monitoring plasma concentrations of perphenazine in clinical practice"],"prefix":"10.1007","volume":"87","author":[{"given":"Lars Bolvig","family":"Hansen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niels-Erik","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"CR1","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/BF00426481","volume":"53","author":"L Bolvig Hansen","year":"1977","unstructured":"Bolvig Hansen L, Larsen N-E (1977) Plasma concentrations of perphenazine and its sulphoxide metabolite during continuous oral treatment. Psychopharmacology 53:127?130","journal-title":"Psychopharmacology"},{"key":"CR2","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1365-2125.1979.tb00900.x","volume":"7","author":"L Bolvig Hansen","year":"1979","unstructured":"Bolvig Hansen L, Elley J, Christensen T, Larsen N-E, Naestoft J, Hvidberg EF (1979) Plasma levels of perphenazine and its major metabolites during simultaneous treatment with anticholinergic drugs. Br J Clin Pharmacol 7:75?80","journal-title":"Br J Clin Pharmacol"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/BF00432736","volume":"74","author":"L Bolvig Hansen","year":"1981","unstructured":"Bolvig Hansen L, Larsen N-E, Vestergaard P (1981) Plasma levels of perphenazine (Trilafon) related to development of extrapyramidal side effects. Psychopharmacology 74:306?309","journal-title":"Psychopharmacology"},{"key":"CR4","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/BF00432245","volume":"78","author":"L Bolvig Hansen","year":"1982","unstructured":"Bolvig Hansen L, Larsen N-E, Gulmann N (1982) Dose-response relationships of perphenazine in the treatment of acute psychoses. Psychopharmacology 78:112?115","journal-title":"Psychopharmacology"},{"key":"CR5","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2165\/00003088-197803010-00002","volume":"3","author":"TB Cooper","year":"1978","unstructured":"Cooper TB (1978) Plasma level monitoring of antipsychotic drugs. Clin Pharmacokinet 3:14?38","journal-title":"Clin Pharmacokinet"},{"key":"CR6","first-page":"15","volume":"14","author":"SE Ericksen","year":"1978","unstructured":"Ericksen SE, Hrut SW, Chang S (1978) Haloperidol dose, plasma levels and clinical response: A double-blind study. Psychopharmacol Bull 14:15?16","journal-title":"Psychopharmacol Bull"},{"key":"CR7","first-page":"156","volume":"18","author":"I Extein","year":"1982","unstructured":"Extein I, Augusthy KA, Gold MS, Pottash ALC, Martin D, Potter WZ (1982) Plasma haloperidol levels and clinical response in acute schizophrenia. Psychopharmacol Bull 18:156?158","journal-title":"Psychopharmacol Bull"},{"key":"CR8","first-page":"396","volume":"21","author":"A Forsman","year":"1977","unstructured":"Forsman A, Ohman R (1977) Applied pharmacokinetics of haloperidol in man. Curr Ther Res 21:396?411","journal-title":"Curr Ther Res"},{"key":"CR9","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1111\/j.1365-2125.1976.tb00647.x","volume":"3","author":"CE Hansen","year":"1976","unstructured":"Hansen CE, Rosted Christensen T, Elley J, Bolvig Hansen L, Kragh-Sorensen P, Larsen N-E, Naestoft J, Hvidberg E (1976) Clinical pharmacokinetic studies of perphenazine. Br J Clin Pharmacol 3:915?923","journal-title":"Br J Clin Pharmacol"},{"key":"CR10","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/clpt.1980.237","volume":"28","author":"P Kragh-Sorensen","year":"1980","unstructured":"Kragh-Sorensen P, Larsen N-E (1980) Factors influencing nortriptyline steady-state kinetics. Clin Pharmacol Ther 28:796?803","journal-title":"Clin Pharmacol Ther"},{"key":"CR11","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1176\/ajp.138.11.1514-a","volume":"138","author":"JR Magliozzi","year":"1981","unstructured":"Magliozzi JR, Hollister LE, Arnold KV, Earle GM (1981) Relationship of serum haloperidol levels to clinical response in schizophrenic patients. Am J Psychiatry 138:365?367","journal-title":"Am J Psychiatry"},{"key":"CR12","first-page":"255","volume-title":"Neuroleptics: Neurochemical, behavioral, and clinical perspectives","author":"HY Meitzer","year":"1983","unstructured":"Meitzer HY, Kane JM, Kolakowska T (1983) Plasma levels of neuroleptics, prolactin levels, and clinical response. In: Coyle JT, Enna SJ (eds) Neuroleptics: Neurochemical, behavioral, and clinical perspectives. Raven, New York, pp 255?281"},{"key":"CR13","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1001\/archpsyc.1979.01780050089011","volume":"36","author":"RC Smith","year":"1979","unstructured":"Smith RC, Crayton J, Dekirmenjian H, Klass D, Davis JM (1979) Blood levels of neuroleptic drugs in nonresponding chronic schizophrenic patients. Arch Gen Psychiatry 36:579?584","journal-title":"Arch Gen Psychiatry"},{"key":"CR14","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1176\/ajp.139.12.1648-c","volume":"139","author":"RC Smith","year":"1982","unstructured":"Smith RC, Vroulis G, Shvartsburd A, Allen R, Lewis N, Schoolar JC, Chojnacki M, Johnson R (1982) RBC and plasma levels of haloperidol and clinical response in schizophrenia. Am J Psychiatry 139:1054?1056","journal-title":"Am J Psychiatry"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00431770.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF00431770\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00431770","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,9]],"date-time":"2019-04-09T18:39:44Z","timestamp":1554835184000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF00431770"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1985,9]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1985,9]]}},"alternative-id":["BF00431770"],"URL":"https:\/\/doi.org\/10.1007\/bf00431770","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[1985,9]]}}}